Trial Profile
IMP321 Phase I Study of Four Increasing Doses (3, 10, 30 and 100 microg) of a New Immunostimulatory Factor (IMP321) Given Alone or as an Adjuvant to a Reference Flu Antigen in Healthy Young Male Volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 16 Jul 2021
Price :
$35
*
At a glance
- Drugs Eftilagimod alpha (Primary) ; Influenza virus vaccine
- Indications Influenza virus infections
- Focus Adverse reactions; Pharmacodynamics
- Sponsors Immutep
- 26 Oct 2009 New trial record